SELECT * FROM `stock_list` WHERE `symbol` = "MGNX" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 SELECT * FROM `stock_list` where symbol='MGNX' AND exchange = 'NAS' limit 0,1 SELECT * FROM `stock_list` WHERE `symbol` = "MGNX" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
MGNX (Macrogenics) Net Debt Paydown Yield %
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Macrogenics's Net Debt Paydown Yield % was -0.88%.
Macrogenics Net Debt Paydown Yield % Historical Data
The historical data trend for Macrogenics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Macrogenics's Net Debt Paydown Yield %
For the Biotechnology subindustry, Macrogenics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics's Net Debt Paydown Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Macrogenics's Net Debt Paydown Yield % falls into.
Macrogenics Net Debt Paydown Yield % Calculation
Macrogenics's Net Debt Paydown Yield % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Macrogenics (NAS:MGNX) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Macrogenics Net Debt Paydown Yield % Related Terms
Thank you for viewing the detailed overview of Macrogenics's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MGNX has been successfully added to your 